NYSE:ATNM Stock Quote

Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Actinium Pharmaceuticals, Inc. (“Actinium” or the “Company”) (NYSE American: ATNM) investors concerning the Company’s possible violations of the federal securities laws.

Law Offices of Howard G. Smith announces an investigation on behalf of Actinium Pharmaceuticals, Inc. (“Actinium” or the “Company”) (NYSE American: ATNM) investors concerning the Company’s possible violations of federal securities laws.

NEW YORK, March 30, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Actinium Pharmaceuticals, Inc. (“Actinium” or the “Company”) (NYSE: ATNM).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers of securities of Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) between October 31, 2022, and August 2, 2024. Actinium describes itself as a “late-stage biopharmaceutical company that develops targeted radiotherapies.”

The Law Offices of Frank R. Cruz announces an investigation of Actinium Pharmaceuticals, Inc. (“Actinium” or the “Company”) (NYSE American: ATNM) on behalf of investors concerning the Company’s possible violations of federal securities laws.

The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Actinium Pharmaceuticals, Inc. (“Actinium” or “the Company”) (NYSE American: ATNM) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Scott+Scott Attorneys at Law LLP (“Scott+Scott”), an international shareholder and consumer rights litigation firm, has filed a securities class action lawsuit in the United States District Court for the Southern District of New York against Actinium Pharmaceuticals, Inc. (“Actinium” or the “Company”) (NYSE American: ATNM), and certain of its former and current officers and/or directors (collectively, “Defendants”). The Class Action asserts claims under §§10(b) and 20(a) of the Securities Exchange Act of 1934 (15 U.S.C. §§78j(b) and 78t(a)) and U.S. Securities and Exchange Commission Rule 10b-5 promulgated thereunder (17 C.F.R. §240.10b-5) on behalf of all persons other than Defendants who purchased or otherwise acquired Actinium securities between October 31, 2022, and August 2, 2024, inclusive (the “Class Period”), and were damaged thereby (the “Class”). The Class Action filed by Scott+Scott is captioned: Kohil v. Actinium Pharmaceuticals, Inc., et al., Case No. 1:25-cv-02553.

New York, NY – March 20, 2025 – Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced that is has entered into a sponsored research agreement with Memorial Sloan Kettering Cancer Center (MSKCC) to expand Actimab-A’s mutation agnostic mechanism of action. The collaboration has […]

EQNX::TICKER_START (NYSE:ATNM),(NYSE:BMY),(NYSE:LLY),(NYSE:NVS),(NASDAQ:AZN) EQNX::TICKER_END

Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Actinium Pharmaceuticals, Inc. (“Actinium” or “the Company”) (NYSE: ATNM). Investors who purchased Actinium securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/ATNM.

Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Actinium Pharmaceuticals, Inc. (“Actinium” or “the Company”) (NYSE: ATNM). Investors who purchased Actinium securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/ATNM.

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Actinium Pharmaceuticals, Inc. (“Actinium” or “the Company”) (NYSE American: ATNM) for violations of the securities laws.

Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - June 18, 2024) - Investorideas.com, a go-to investing platform covering biotech and...

Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) a leader in the development of Antibody Radiation Conjugates (ARCs) and other targeted radiotherapies announced that an abstract detailing the first ever preclinical data from the combination of menin inhibitors with Actinium's ARC Actimab-A in acute myeloid leukemia (AML) models was presented at the 2024 European Hematology Association (EHA) Congress held June 13 – 16, 2024, in Madrid, Spain.

EQNX::TICKER_START (NYSE:ATNM),(NASDAQ:BPTH),(NASDAQ:LGVN),(NASDAQ:SLS),(NYSE:BMY) EQNX::TICKER_END

EQNX::TICKER_START (NYSE:ATNM),(NASDAQ:SNDX),(NASDAQ:KURA),(NASDAQ:BMEA),(NYSE:JNJ) EQNX::TICKER_END

PALM BEACH, Fla., June 17, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - According to a report from Mordor Intelligence the Acute Myeloid Leukemia Market size is estimated at USD 1.83 billion in 2024, and is expected to reach USD 2.97 billion by 2029, growing at a CAGR of 10.15% during the forecast period (2024-2029). The report said: “Key factors propelling the growth of this market are the high incidence and prevalence of acute myeloid leukemia, advancements in pharmacology and molecular biology to promote drug development and increasing investments in research and development by pharmaceutical companies. According to the American Cancer Society, it is estimated that there will be 60,650 new leukemia cancer cases, of which 24,000 are expected to die in 2022 in the US. In addition, according to the same source, 20,050 new cases of acute myeloid leukemia (AML) are estimated in 2022 in the US. It will lead to increased adoption of AML therapies. The rising prevalence of AML in developed countries such as the US is expected to drive this market's growth. Furthermore, with the rising investment in research and development, there is an increasing number of clinical trials conducted to demonstrate the effectiveness of the drugs. It is expected to drive the market over the forecast period.” Active biotech and pharma companies in the markets this week include Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM), Bio-Path Holdings, Inc., (NASDAQ: BPTH), Longeveron (NASDAQ: LGVN), SELLAS Life Sciences Group, Inc. (NASDAQ: SLS), Bristol Myers Squibb (NYSE: BMY).

Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - June 17, 2024) - Investorideas.com, a go-to investing platform, releases the first...

Actimab-A enhances dose-dependent acute myeloid leukemia cell death in KMT2A sensitive acute myeloid leukemia blasts in combination with leading menin inhibitors Combination with leading menin inhibitor demonstrates acute myeloid leukemia cell death and significant tumor elimination not achieved with monotherapy Menin combination expands backbone potential of Actimab-A in acute myeloid leukemia that already includes chemotherapy, […]

DelveInsight's analysts estimate that relapsed/refractory acute myeloid leukemia market is poised to show significant growth, mainly attributed to recent drug approvals, increasing incidence, and anticipated launch of novel therapies during the forecast period (2023–2032).

In the realm of investing, the biotech sector often resembles a high-stakes poker game. The volatility inherent in this field, especially within the under-$10 stock category, can turn even a seasoned investor's stomach. Yet, for those with an appetite for risk and an eye for potential, there lies significant opportunity. One such opportunity is Actinium Pharmaceuticals (NYSEAMERICAN: ATNM), a New York-based biopharmaceutical company that is making waves with its pioneering targeted radiotherapies.

Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) is increasingly regarded as a prime acquisition candidate amidst a surge of mergers and acquisitions (M&A) activity in the radiopharmaceutical sector. Recent deals, such as Novartis's acquisition of Mariana Oncology and AstraZeneca's purchase of Fusion Pharma, have underscored the vibrant investment interest in this niche of the oncology market.

In a landscape marked by uncertain economic signals and heated debates over monetary policy, the biotech industry stands out as a beacon of innovation and growth potential. Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM), with its groundbreaking advancements in targeted radiotherapies, underscores the burgeoning appeal of biotech investments amidst these turbulent times.

In the current economic backdrop where the Federal Reserve maintains a cautious stance on interest rate adjustments amid ongoing inflation concerns, the biotech sector emerges as an especially promising field for investors. The anticipation surrounding rate cuts, now deferred to possibly September as per the latest consumer price data, sets a unique stage for biotech stocks, which historically perform well in the months leading to such financial shifts.

Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM), a pioneer in the development of Antibody Radiation Conjugates (ARCs) and targeted radiotherapies, is steering transformative advancements in cancer treatment through its clinical trials and strategic production enhancements. The company has also been a central figure in the burgeoning mergers and acquisitions landscape within the radiopharmaceutical sector.